Clinica trial PHASE I-II of LEDC (Liposomal Encapsulated Doxorubicin Cytrate, Myocet) + CARBOPLATIN IN EPITHELIAL ginecological CANCER [Estudio Fase I-II multicéntrico, abierto, de la combinación de doxorrubicina liposomal encapsulada (Myocet) y carboplatino en el tratamiento de pacientes con cáncer ginecológico o peritoneal primario recurrente].

Trial Profile

Clinica trial PHASE I-II of LEDC (Liposomal Encapsulated Doxorubicin Cytrate, Myocet) + CARBOPLATIN IN EPITHELIAL ginecological CANCER [Estudio Fase I-II multicéntrico, abierto, de la combinación de doxorrubicina liposomal encapsulada (Myocet) y carboplatino en el tratamiento de pacientes con cáncer ginecológico o peritoneal primario recurrente].

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 02 Jun 2015

At a glance

  • Drugs Carboplatin (Primary) ; Doxorubicin liposomal (Primary)
  • Indications Cervical cancer; Endometrial cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 02 Jun 2015 Results for the phase I portion in 23 evaluable patients presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 02 Jun 2015 The phase I portion has been completed and the phase II portion is in progress, as reported at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 15 Jan 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top